Some drugs for COVID-19
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:62 |
|---|---|
| Enthalten in: |
The Medical letter on drugs and therapeutics - 62(2020), 1595 vom: 06. Apr., Seite 49-50 |
| Sprache: |
Englisch |
|---|
| Anmerkungen: |
Date Completed 28.04.2020 Date Revised 07.12.2022 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM309085470 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM309085470 | ||
| 003 | DE-627 | ||
| 005 | 20231225133133.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n1030.xml |
| 035 | |a (DE-627)NLM309085470 | ||
| 035 | |a (NLM)32324177 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Some drugs for COVID-19 |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.04.2020 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a ACE inhibitors | |
| 650 | 4 | |a ARBs | |
| 650 | 4 | |a Actemra | |
| 650 | 4 | |a Advil | |
| 650 | 4 | |a HIV | |
| 650 | 4 | |a Kaletra | |
| 650 | 4 | |a Kevzara | |
| 650 | 4 | |a Motrin | |
| 650 | 4 | |a NSAIDs | |
| 650 | 4 | |a Plaquenil | |
| 650 | 4 | |a Tylenol | |
| 650 | 4 | |a acetaminophen | |
| 650 | 4 | |a adverse effects | |
| 650 | 4 | |a angiotensin receptor blockers | |
| 650 | 4 | |a antiretrovirals | |
| 650 | 4 | |a azithromycin | |
| 650 | 4 | |a chloroquine | |
| 650 | 4 | |a coronavirus | |
| 650 | 4 | |a corticosteroids | |
| 650 | 4 | |a hydroxychloroquine | |
| 650 | 4 | |a ibuprofen | |
| 650 | 4 | |a lopinavir | |
| 650 | 4 | |a oseltamivir | |
| 650 | 4 | |a remdesivir | |
| 650 | 4 | |a ribavirin | |
| 650 | 4 | |a ritonavir | |
| 650 | 4 | |a safety | |
| 650 | 4 | |a sarilumab | |
| 650 | 4 | |a tocilizumab | |
| 650 | 7 | |a Adrenal Cortex Hormones |2 NLM | |
| 650 | 7 | |a Angiotensin Receptor Antagonists |2 NLM | |
| 650 | 7 | |a Angiotensin-Converting Enzyme Inhibitors |2 NLM | |
| 650 | 7 | |a Anti-Inflammatory Agents, Non-Steroidal |2 NLM | |
| 650 | 7 | |a Drug Combinations |2 NLM | |
| 650 | 7 | |a lopinavir-ritonavir drug combination |2 NLM | |
| 650 | 7 | |a Lopinavir |2 NLM | |
| 650 | 7 | |a 2494G1JF75 |2 NLM | |
| 650 | 7 | |a remdesivir |2 NLM | |
| 650 | 7 | |a 3QKI37EEHE |2 NLM | |
| 650 | 7 | |a Adenosine Monophosphate |2 NLM | |
| 650 | 7 | |a 415SHH325A |2 NLM | |
| 650 | 7 | |a Hydroxychloroquine |2 NLM | |
| 650 | 7 | |a 4QWG6N8QKH |2 NLM | |
| 650 | 7 | |a Azithromycin |2 NLM | |
| 650 | 7 | |a 83905-01-5 |2 NLM | |
| 650 | 7 | |a Chloroquine |2 NLM | |
| 650 | 7 | |a 886U3H6UFF |2 NLM | |
| 650 | 7 | |a Neuraminidase |2 NLM | |
| 650 | 7 | |a EC 3.2.1.18 |2 NLM | |
| 650 | 7 | |a Ritonavir |2 NLM | |
| 650 | 7 | |a O3J8G9O825 |2 NLM | |
| 650 | 7 | |a Alanine |2 NLM | |
| 650 | 7 | |a OF5P57N2ZX |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t The Medical letter on drugs and therapeutics |d 1965 |g 62(2020), 1595 vom: 06. Apr., Seite 49-50 |w (DE-627)NLM000074810 |x 1523-2859 |7 nnns |
| 773 | 1 | 8 | |g volume:62 |g year:2020 |g number:1595 |g day:06 |g month:04 |g pages:49-50 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 62 |j 2020 |e 1595 |b 06 |c 04 |h 49-50 | ||